Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International consensus on radiotherapy in metastatic non-small cell lung cancer.
Zhu Z, Ni J, Cai X, Su S, Zhuang H, Yang Z, Chen M, Ma S, Xie C, Xu Y, Li J, Ge H, Liu A, Zhao L, Rao C, Xie C, Bi N, Hui Z, Zhu G, Yuan Z, Wang J, Zhao L, Zhou W, Rim CH, Navarro-Martin A, Vanneste BGL, Ruysscher D, Choi JI, Jassem J, Chang JY, Kepka L, Käsmann L, Milano MT, Van Houtte P, Suwinski R, Traverso A, Doi H, Suh YG, Noël G, Tomita N, Kowalchuk RO, Sio TT, Li B, Lu B, Fu X. Zhu Z, et al. Among authors: ruysscher d. Transl Lung Cancer Res. 2022 Sep;11(9):1763-1795. doi: 10.21037/tlcr-22-644. Transl Lung Cancer Res. 2022. PMID: 36248338 Free PMC article. Review.
Postoperative radiotherapy for lung cancer: Is it worth the controversy?
Billiet C, Peeters S, Decaluwé H, Vansteenkiste J, Mebis J, Ruysscher D. Billiet C, et al. Among authors: ruysscher d. Cancer Treat Rev. 2016 Dec;51:10-18. doi: 10.1016/j.ctrv.2016.10.001. Epub 2016 Oct 14. Cancer Treat Rev. 2016. PMID: 27788387 Review.
Particle therapy in lung cancer: where do we stand?
Pijls-Johannesma M, Grutters JP, Lambin P, Ruysscher DD. Pijls-Johannesma M, et al. Cancer Treat Rev. 2008 May;34(3):259-67. doi: 10.1016/j.ctrv.2007.12.003. Epub 2008 Jan 15. Cancer Treat Rev. 2008. PMID: 18226466 Review.
Transition from a simple to a more advanced dose calculation algorithm for radiotherapy of non-small cell lung cancer (NSCLC): implications for clinical implementation in an individualized dose-escalation protocol.
Elmpt Wv, Ollers M, Velders M, Poels K, Mijnheer B, Ruysscher DD, Dekker A, Lambin P, Boersma L. Elmpt Wv, et al. Radiother Oncol. 2008 Sep;88(3):326-34. doi: 10.1016/j.radonc.2008.07.003. Epub 2008 Aug 11. Radiother Oncol. 2008. PMID: 18701177
FDG for dose painting: a rational choice.
Aerts HJ, Lambin P, Ruysscher DD. Aerts HJ, et al. Radiother Oncol. 2010 Nov;97(2):163-4. doi: 10.1016/j.radonc.2010.05.001. Epub 2010 Jun 17. Radiother Oncol. 2010. PMID: 20561697 No abstract available.
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA, Belderbos JSA, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, van Diessen JNA, Sonke JJ, de Ruysscher D. Cooke SA, et al. Among authors: de ruysscher d. Radiother Oncol. 2024 Apr 24;196:110312. doi: 10.1016/j.radonc.2024.110312. Online ahead of print. Radiother Oncol. 2024. PMID: 38663582
Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes.
Gullhaug A, Haakensen VD, De Ruysscher D, Simone CB 2nd, Hotca-Cho AE, Chhabra AM, Hellebust TP, Paulsen EE, Dimopoulos MP, Johansen S. Gullhaug A, et al. Among authors: de ruysscher d. J Med Imaging Radiat Sci. 2024 Feb 29:S1939-8654(24)00018-3. doi: 10.1016/j.jmir.2024.02.004. Online ahead of print. J Med Imaging Radiat Sci. 2024. PMID: 38429174 Free article.
495 results